Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Receivables (2021 - 2025)

Historic Receivables for Nurix Therapeutics (NRIX) over the last 5 years, with Q2 2025 value amounting to $20.7 million.

  • Nurix Therapeutics' Receivables changed N/A to $20.7 million in Q2 2025 from the same period last year, while for May 2025 it was $20.7 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Nurix Therapeutics reported Receivables of $20.7 million as of Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Receivables ranged from a high of $20.7 million in Q2 2025 and a low of $1.0 million during Q4 2022
  • Moreover, its 5-year median value for Receivables was $6.9 million (2021), whereas its average is $6.9 million.
  • Over the last 5 years, Nurix Therapeutics' Receivables had its largest YoY gain of 8550.72% in 2022, and its largest YoY loss of 8550.72% in 2022.
  • Nurix Therapeutics' Receivables (Quarter) stood at $6.9 million in 2021, then tumbled by 85.51% to $1.0 million in 2022, then soared by 700.0% to $8.0 million in 2023, then crashed by 81.25% to $1.5 million in 2024, then skyrocketed by 1280.0% to $20.7 million in 2025.
  • Its Receivables stands at $20.7 million for Q2 2025, versus $1.5 million for Q4 2024 and $8.0 million for Q3 2023.